search
Back to results

ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments (ED2PrEP)

Primary Purpose

HIV

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PVO
TS
Sponsored by
Viraj V. Patel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 years and older;
  • visit to the Emergency Department,
  • has a sexual health related concern

Exclusion Criteria:

  • unable to provide informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Post Visit Outreach

    Tele-Sexual Healthcare

    Arm Description

    Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.

    Tele-sexual health visit with a specialist offered during the ED visit to patients.

    Outcomes

    Primary Outcome Measures

    PrEP Uptake
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.

    Secondary Outcome Measures

    PrEP Uptake at 6 months
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.
    PrEP Uptake at 12 months
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.
    Linkage to status neutral healthcare
    Attending a clinical appointment for sexual healthcare or related to HIV, captured in the electronic health record
    Linkage to status neutral healthcare
    Attending a clinical appointment for sexual healthcare or related to HIV, captured in the electronic health record
    HIV and STI testing
    Receipt of tests for HIV and sexually transmitted infections (gonorrhea and chlamydia from any anatomic site, or syphilis) after the emergency department visit, captured in the electronic health record.
    PrEP Persistence
    Composite data from the electronic health record about having a prescription for PrEP medications and survey responses about current PrEP use.
    PrEP Persistence
    Composite data from electronic health record about having a prescription for PrEP medications and survey responses about current PrEP use.
    HIV Viral RNA levels
    Laboratory quantification of circulating HIV virus among individuals diagnosed with HIV in the study.
    HIV Viral RNA levels
    Laboratory quantification of circulating HIV virus among individuals diagnosed with HIV in the study.
    Incident HIV Diagnosis
    Diagnosis of HIV based on multiple data sources (electronic health record, surveys) occurring at anytime starting from ED visit through end of study period.

    Full Information

    First Posted
    October 7, 2022
    Last Updated
    October 18, 2022
    Sponsor
    Viraj V. Patel
    Collaborators
    National Institute of Allergy and Infectious Diseases (NIAID)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05588193
    Brief Title
    ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments
    Acronym
    ED2PrEP
    Official Title
    ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments Patients: a Cross-over Hybrid Implementation Effectiveness Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    April 2025 (Anticipated)
    Study Completion Date
    July 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Viraj V. Patel
    Collaborators
    National Institute of Allergy and Infectious Diseases (NIAID)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Severe inequities in HIV pre-exposure prophylaxis (PrEP) access and use in communities hardest hit by the HIV epidemic persist, further exacerbating ongoing racial/ethnic and socioeconomic disparities in HIV incidence. In these same communities, many patients at risk for HIV seek care for sexually transmitted infections (STIs) in Emergency Departments (EDs), but the structure of traditional ED care is poorly suited to address HIV prevention or provide PrEP. To advance the Prevent objective of the Ending the HIV Epidemic (EHE) initiative, ED2PrEP will leverage an implementation science approach to rigorously test two innovative strategies for increasing PrEP uptake among patients seeking STI care in EDs in one of the 48 EHE-identified geographic hotspots.
    Detailed Description
    Severe inequities in HIV pre-exposure prophylaxis (PrEP) access and use persist among Black and Latinx communities most impacted by the HIV epidemic. The Bronx, NY, with over 90% of the population identifying as Black or Latinx, is an Ending the HIV Epidemic (EHE) priority county with the fifth highest HIV diagnosis rate in the U.S. and the lowest PrEP use in NY. Research on barriers to PrEP engagement indicate that the current structure of PrEP access and management is not consonant with the lives, priorities, or needs of the hardest hit communities, further exacerbating ongoing racial/ethnic and socioeconomic disparities in HIV incidence. Many of the same barriers leading to poor PrEP uptake in Black/Latinx communities also drive members of these communities to seek care for sexually transmitted infections (STIs), a known risk factor for HIV, in Emergency Departments (EDs). However, there is a discordance between the type of care likely to preserve the long-term health of those seeking STI care in EDs (longitudinal, behavioral, and prevention-oriented) and the care the ED is optimized to provide (acute, high intensity, life-saving/stabilizing), meaning that both patients and health systems stand to gain from a restructuring of how STI care is delivered in EDs. Innovative, efficient, and sustainable strategies for identifying and engaging high priority populations for HIV prevention seeking sexual healthcare in EDs are thus needed. The study team therefore proposes ED2PrEP, a pragmatic Type III hybrid effectiveness-implementation trial comparing two strategies for increasing PrEP uptake among patients at risk for HIV accessing care in Bronx EDs. The two strategies are (1) Post-Visit Outreach (PVO) involving proactive outreach to patients following a STI-related ED visit. PVO will be initiated by a Sexual Health Navigator who will provide PrEP education, counseling, and linkage to existing sexual health/PrEP clinics. (2) Tele-PrEP (TP) will involve a real-time telehealth visit with a Sexual Health Provider during STI-related ED visits. TP will also include education, counseling, and linkage, in addition to the provider's ability to prescribe PrEP at the time of the visit. To test the effectiveness of PVO and TP for increasing PrEP uptake among patients accessing STI care in the ED, the study team will perform a crossover trial in which the strategies are implemented in two different EDs for 9 months and then switched for another 9 months (Aim 1). Next, guided by the RE-AIM framework, the study team will assess implementation outcomes for the strategies to identify how each strategy's effectiveness is impacted by implementation considerations (Aim 2). Finally, to inform scale-out locally and nationally, the study team will perform an economic analysis to determine each strategy's cost per outcome and relative cost-effectiveness (Aim 3). ED2PrEP will generate critical data that could transform how EDs initiate PrEP and engage populations at the highest risk for HIV and accelerate EHE goals in one hardest hit jurisdictions in the U.S. Findings could also be informative to other jurisdictions, having dramatic effects on how HIV prevention is delivered.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HIV

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    InvestigatorOutcomes Assessor
    Allocation
    Non-Randomized
    Enrollment
    1000 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Post Visit Outreach
    Arm Type
    Experimental
    Arm Description
    Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.
    Arm Title
    Tele-Sexual Healthcare
    Arm Type
    Experimental
    Arm Description
    Tele-sexual health visit with a specialist offered during the ED visit to patients.
    Intervention Type
    Behavioral
    Intervention Name(s)
    PVO
    Intervention Description
    post-visit outreach
    Intervention Type
    Behavioral
    Intervention Name(s)
    TS
    Intervention Description
    tele-sexual health visit during the ED visit
    Primary Outcome Measure Information:
    Title
    PrEP Uptake
    Description
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    PrEP Uptake at 6 months
    Description
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.
    Time Frame
    6 months
    Title
    PrEP Uptake at 12 months
    Description
    Prescription of any medication to be used as HIV PrEP, captured in the electronic health record.
    Time Frame
    12 months
    Title
    Linkage to status neutral healthcare
    Description
    Attending a clinical appointment for sexual healthcare or related to HIV, captured in the electronic health record
    Time Frame
    3 months
    Title
    Linkage to status neutral healthcare
    Description
    Attending a clinical appointment for sexual healthcare or related to HIV, captured in the electronic health record
    Time Frame
    12 months
    Title
    HIV and STI testing
    Description
    Receipt of tests for HIV and sexually transmitted infections (gonorrhea and chlamydia from any anatomic site, or syphilis) after the emergency department visit, captured in the electronic health record.
    Time Frame
    6 months
    Title
    PrEP Persistence
    Description
    Composite data from the electronic health record about having a prescription for PrEP medications and survey responses about current PrEP use.
    Time Frame
    6 months
    Title
    PrEP Persistence
    Description
    Composite data from electronic health record about having a prescription for PrEP medications and survey responses about current PrEP use.
    Time Frame
    12 months
    Title
    HIV Viral RNA levels
    Description
    Laboratory quantification of circulating HIV virus among individuals diagnosed with HIV in the study.
    Time Frame
    3 months
    Title
    HIV Viral RNA levels
    Description
    Laboratory quantification of circulating HIV virus among individuals diagnosed with HIV in the study.
    Time Frame
    12 months
    Title
    Incident HIV Diagnosis
    Description
    Diagnosis of HIV based on multiple data sources (electronic health record, surveys) occurring at anytime starting from ED visit through end of study period.
    Time Frame
    18 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: 18 years and older; visit to the Emergency Department, has a sexual health related concern Exclusion Criteria: unable to provide informed consent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Uriel Felsen, MD, MS
    Phone
    7189208588
    Email
    ufelsen@montefiore.org
    First Name & Middle Initial & Last Name or Official Title & Degree
    Viraj V Patel, MD, MPH
    Phone
    7189205256
    Email
    vpatel@montefiore.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Uriel Felsen, MD, MS
    Organizational Affiliation
    Albert Einstein College of Medicine
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Viraj V Patel, MD, MPH
    Organizational Affiliation
    Albert Einstein College of Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    All deidentified participant level data related to study outcomes.
    IPD Sharing Time Frame
    6 months after publication of primary outcomes for 5 years.
    IPD Sharing Access Criteria
    Appropriate IRB approvals, research plans approved by study MPIs, and data sharing agreements executed.

    Learn more about this trial

    ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments

    We'll reach out to this number within 24 hrs